modelR06AX13

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Loratadine
ATC code:R06AX13
route:oral
compartments:1
dosage:10mg
volume of distribution:119L
clearance:9.27L/h
other parameters in model implementation

Loratadine is a second-generation, non-sedating antihistamine used to relieve symptoms of allergy such as sneezing, runny nose, and itchy eyes. It is commonly prescribed for the treatment of allergic rhinitis and urticaria, and is approved for use in many countries worldwide.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following single oral dose.

References

  1. Liu, T, et al., & Liu, X (2024). Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole-Body Physiologically Based Pharmacokinetic Model. Journal of clinical pharmacology None –. DOI:10.1002/jcph.6120 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39171895

  2. Salem, II, et al., & Idkaidek, NM (2010). A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. Clinical therapeutics 32(2) 391–395. DOI:10.1016/j.clinthera.2010.02.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20206796

  3. Zhang, YF, et al., & Dong, YM (2003). Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta pharmacologica Sinica 24(7) 715–718. PUBMED:https://pubmed.ncbi.nlm.nih.gov/12852841

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)